Market Overview

UPDATE: Credit Suisse Initiates Regeneron Pharmaceutical at Outperform

Related REGN
UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following Good Results Of Drug Study
Benzinga's Top #PreMarket Gainers

Credit Suisse initiales coverage on Regeneron Pharmaceutical (NASDAQ: REGN) with an Outperform rating and a $187 price target.

Credit Suisse said, "The primary value driver remains quarterly sales of Eylea. Proposed legislation regulating compounding pharmacies, a permanent J code in January and the launch in RVO could all help boost sales. Competitor data for Amgen's AMG145 (anti-PCSK9) and Ophthotech's Fovista have all recently been disclosed, and key clinical data for Regeneron are limited in the near term."

Regeneron Pharmaceutical closed at $144.90 on Monday.

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (REGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters